Fig. 9

High expression of BID associates with response to SAC abrogation in patient-derived xenografts (PDXs). A Athymic nude mice bearing CTG-3429, CTG-1059 and CTG-3283 PDXs were treated with vehicle or an AZD2811 nanoparticle formulation (25 mg/kg) once weekly, as indicated by arrows. Panels show tumor volumes as measured by caliper (mean ± SEM). The number of mice per group is indicated in the plots. B Average levels of BID mRNA, as quantified by RT-Q-PCR, in fresh tissue of CTG-3283 (inverted triangle, n=5), CTG3429 and CTG-1059 (diamonds, n=6) patient-derived xenografts. BID mRNA levels in fresh cultures of cell lines sensitive (green dots) and resistant (red dots) to SAC abrogation are also plotted. C Quantification of the BID bands in the Western blotting analyses of PDXs (shown in Figs 9I and S18F). D Western blotting analysis of BID protein in vehicle-treated (V1, V2) PDXs. The results for the rest of PDXs tested are shown in Fig. S18F. E Western blotting analysis of CASP-2 and the AURKB product phosphor-histone H3 (pH3) in CTG-3282 patient-derived xenografts. V1-V3, xenografts treated with vehicle; A1-A2, xenografts treated with AZD2811. F Immunodeficient female mice bearing ST3632, DCFI-403, CTG-2939 and DCFI-367 PDXs were treated with vehicle or an AZD2811 nanoparticle formulation (25 mg/kg) once weekly, as indicated by arrows. Tumor volumes as measured by caliper are shown (mean ± SEM). The number of mice per group is indicated in the plots. G FISH analysis of ST3632 xenografts, revealing 4.6 copies of HIRA, CRKL and MAPK1 per cell (upper panel) and a ratio of 2.1 of HIRA to the Chr22 telomeric gene SHANK3 (lower panel). (H) BID mRNA levels in the NSCLC PDXs presented in (F), as calculated from RNA seq data. The Z-scores and log2 (value + 1) are presented